跳至主要内容
临床试验/JPRN-jRCT1050230049
JPRN-jRCT1050230049招募中Unknown

Observational study to evaluate the impact of heterogeneities of RAS/BRAF in tissue and ctDNA on the efficacy of anti EGFR antibody in advanced colorectal cancer - RAS-trace 2

Kozo Kataoka0 个研究点目标入组 240 人开始时间: 2023年6月24日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1)Histologically proven for colorectal cancer
  • 2)Clinical Stage IV or recurrent colorectal cancer for which more than 12 cycles of chemotherapy including anti-EGFR therapy is planned.
  • 3)measurable lesions according to RECIST ver1.1
  • 4)Presence of liver metastases
  • 5) No previous history of chemotherapy and radiotherapy
  • 6)Aged 20 years old and over
  • 7)ECOG PS0-1
  • 8)Consent for blood exam for ctDNA analy
  • 9)Written informed consen

排除标准

  • 1)Active other malignancies
  • 2)Histologically confirmed for MMRD (MSI-H or dMMR)
  • 3)Pregnancy, possible pregnancy or breastfeeding
  • 4)Severe pulmonary fibrosis or emphysema
  • 5)Psychiatric disease
  • 6)Patients requiring systemic steroid medication
  • 7) Grade 2 or greater diarrhea or sensory neuropathy
  • 8)Poorly controlled hypertension
  • 9)History of severe heart disease, heart failure, unstable angina within 6 months or angina attack with 6 months
  • 10) active COVID-19 infection

研究者

发起方
Kozo Kataoka

相似试验